Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Checkpoint inhibition
Chemoradiotherapy
PDL1
Prognostic factors
TILs
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
02 Jan 2020
02 Jan 2020
Historique:
received:
09
08
2019
accepted:
23
12
2019
entrez:
4
1
2020
pubmed:
4
1
2020
medline:
21
8
2020
Statut:
epublish
Résumé
mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Increasing evidence suggests treatment outcome depending on tumor cell PD-L1 expression. The purpose of this retrospective study was to investigate the prognostic value of PD-L1 expression on tumor cells in combination with CD8+ tumor stroma-infiltrating lymphocyte (TIL) density in inoperable LA-NSCLC treated with concurrent chemoradiotherapy (CRT). We retrospectively assessed clinical characteristics and initial tumor biopsy samples of 31 inoperable LA-NSCLC patients treated with concurrent CRT. Prognostic impact of tumor cell PD-L1 expression (0% versus ≥1%) and CD8+ TIL density (0-40% vs. 41-100%) for local control, progression-free (PFS) and overall survival (OS) as well as correlations with clinicopathological features were evaluated. Median OS was 14 months (range: 3-167 months). The OS rates at 1- and 2 years were 68 and 20%. Local control of the entire cohort at 1 and 2 years were 74 and 61%. Median PFS, 1-year and 2-year PFS were 13 ± 1.4 months, 58 and 19%. PD-L1 expression < 1% on tumor cells was associated with improved OS, PFS and local control in patients treated with concurrent CRT. Univariate analysis showed a trend towards improved OS and local control in patients with low CD8+ TIL density. Evaluation of Tumor Immunity in the MicroEnvironment (TIME) appears to be an independent prognostic factor for local control, PFS and OS. The longest and shortest OS were achieved in patients with type I (PD-L1 Assessment of PD-L1 expression on tumor cells in combination with CD8+ TIL density can be a predictive biomarker in patients with inoperable LA-NSCLC treated with concurrent CRT.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Increasing evidence suggests treatment outcome depending on tumor cell PD-L1 expression. The purpose of this retrospective study was to investigate the prognostic value of PD-L1 expression on tumor cells in combination with CD8+ tumor stroma-infiltrating lymphocyte (TIL) density in inoperable LA-NSCLC treated with concurrent chemoradiotherapy (CRT).
PATIENTS AND METHOD
METHODS
We retrospectively assessed clinical characteristics and initial tumor biopsy samples of 31 inoperable LA-NSCLC patients treated with concurrent CRT. Prognostic impact of tumor cell PD-L1 expression (0% versus ≥1%) and CD8+ TIL density (0-40% vs. 41-100%) for local control, progression-free (PFS) and overall survival (OS) as well as correlations with clinicopathological features were evaluated.
RESULTS
RESULTS
Median OS was 14 months (range: 3-167 months). The OS rates at 1- and 2 years were 68 and 20%. Local control of the entire cohort at 1 and 2 years were 74 and 61%. Median PFS, 1-year and 2-year PFS were 13 ± 1.4 months, 58 and 19%. PD-L1 expression < 1% on tumor cells was associated with improved OS, PFS and local control in patients treated with concurrent CRT. Univariate analysis showed a trend towards improved OS and local control in patients with low CD8+ TIL density. Evaluation of Tumor Immunity in the MicroEnvironment (TIME) appears to be an independent prognostic factor for local control, PFS and OS. The longest and shortest OS were achieved in patients with type I (PD-L1
CONCLUSION
CONCLUSIONS
Assessment of PD-L1 expression on tumor cells in combination with CD8+ TIL density can be a predictive biomarker in patients with inoperable LA-NSCLC treated with concurrent CRT.
Identifiants
pubmed: 31898519
doi: 10.1186/s13014-019-1453-3
pii: 10.1186/s13014-019-1453-3
pmc: PMC6941268
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Références
J Egypt Natl Canc Inst. 2018 Dec;30(4):125-131
pubmed: 30337185
J Immunother. 2018 Feb/Mar;41(2):96-99
pubmed: 29200082
Cancer Med. 2018 Jan;7(1):32-45
pubmed: 29168339
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Strahlenther Onkol. 2018 Feb;194(2):79-90
pubmed: 29030654
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Eur J Cancer. 2016 Mar;55:7-14
pubmed: 26771872
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Blood. 2009 Jul 16;114(3):589-95
pubmed: 19349616
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Oncotarget. 2017 Apr 11;8(35):58457-58468
pubmed: 28938570
Sci Rep. 2017 Sep 12;7(1):11373
pubmed: 28900290
Eur J Cancer. 2018 Sep;101:181-190
pubmed: 30077123
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Radiat Oncol. 2018 Jul 17;13(1):131
pubmed: 30016964
Clin Oncol (R Coll Radiol). 2017 Nov;29(11):e177-e185
pubmed: 28780009
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Eur J Surg Oncol. 2015 Apr;41(4):450-6
pubmed: 25682184
Cancer Biol Med. 2016 Jun;13(2):157-70
pubmed: 27458525
J Thorac Oncol. 2016 Mar;11(3):300-11
pubmed: 26723244
Oncoimmunology. 2018 Mar 19;7(7):e1442999
pubmed: 29900052
J Thorac Oncol. 2019 Jan;14(1):124-129
pubmed: 30138764
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821
pubmed: 30006423
J Immunol Res. 2018 Aug 8;2018:6984948
pubmed: 30159341
Radiol Oncol. 2018 Feb 21;52(3):281-288
pubmed: 30210037
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Radiat Oncol. 2017 Jul 21;12(1):122
pubmed: 28732516
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2103-2109
pubmed: 29876620
J Thorac Oncol. 2015 Jul;10(7):985-9
pubmed: 26134220
Int J Radiat Oncol Biol Phys. 2019 Mar 2;:null
pubmed: 30836168
Sci Rep. 2019 Jan 24;9(1):566
pubmed: 30679441
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Eur J Cancer. 2019 Feb;108:50-54
pubmed: 30648629
Anticancer Res. 2018 Oct;38(10):5897-5901
pubmed: 30275216
JAMA Oncol. 2016 Nov 1;2(11):1403-1404
pubmed: 27490017
Diagn Pathol. 2016 Oct 8;11(1):95
pubmed: 27717372
Cancer Res Treat. 2019 Jul;51(3):1086-1097
pubmed: 30428640
Cancer Invest. 2018 Apr 21;36(4):238-245
pubmed: 29775109
Oncoimmunology. 2017 Feb 6;6(3):e1288331
pubmed: 28405521
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977